Industries + Sectors

At Global PMI Partners we work with clients across many industry sectors. Our approach to consulting necessarily requires teamwork and collaboration with you because we believe that no one external knows your industry or your business like you do. However, healthcare trends and specifics do impact M&A strategy and execution which vary from other industries. We understand these and bring lessons, customized solutions and proven experience from other healthcare M&A deals.

Industry trends

• Growing cost of R&D – becomes a key competitive issue (leverage of acquisitions and open innovation)
• Growing safety and compliance rules – becomes a key cost element
• Maturation of recent production countries – India, China,…and growing roles in the overall pharma value chain
• International development of social security systems – increased public spendings and regulation impacts
• Development of new pharma areas and medical science (genetics, biotech, data science,…)
• Environmental constraints

M&A trends

• Consolidation continued by major groups (Sanofi, Bayer,…)
• Tax-related deals under governmental scrutiny (Pfizer-Allergan)
• Portfolio optimization with carve-outs and asset-swaps (Sanofi-Boehringer,…)

PMI challenges specific to this sector

• R&D-related topics (retention of talents, pipeline management, testing processes, compliance and regulation management)
• Sales-related topics (salesforce rationalization, back-office optimization,
• CRM systems integration,…)
• IS integration (support functions, manufacturing, and supply chain)
• Branding
• IP
• Cultural integration – international transformation – change management
• Data security
• Tax compliance vs tax optimization

How we can help

• Support cross-border acquisitions via local expertise and IMO expertise
• Provide high-value add support on key pharma workstreams (R&D, compliance)
• Support carve-out programs in portfolio reorganization strategies

Global PMI Partners specific value prop

• International presence, in particular, is very active pharma markets (UK, US, France, Germany, Israel, India)
• Strategic partnership with healthcare expert firm (ISS)
• Very significant logistic and IT expertise
• High-leverage consulting model – optimization of internal skills